[Studies on estramustine-binding protein in the human prostate].
In the present study, size exclusion HPLC was used to analyse the properties of Estramustine-binding protein (EMBP) in the cytosol of human benign prostatic hypertrophy (BPH). The typical size exclusion HPLC separation profile of 3H-Estramustine-labelled cytosol of BPH showed four radioactive peaks that corresponded to the V0, 250K, 68K and 45K protein regions. The specific binding protein for Estramustine is contained mainly in the 250K protein region and in part in the V0 region. In the presence of sodium molybdate, the specific Estramustine binding to a 250K protein was increased to a level which was about 2.5 times as much as the value in the absence of sodium molybdate. The specific Estramustine binding to a 250K protein under the condition of no DCC treatment and the addition of sodium molybdate was 600% of the value obtained under the condition of DCC treatment and no addition of sodium molybdate. These results suggested that sodium molybdate stabilized the specific Estramustine-binding activity to a 250K protein and that specific Estramustine binding to a 250K protein seemed to be weaker than the binding of androgen to androgen receptor.
D002352:Carrier Proteins / Q000032:analysis*; D002606:Charcoal; D002851:Chromatography, High Pressure Liquid; D003600:Cytosol / Q000032:analysis; D003911:Dextrans; D006801:Humans; D008297:Male; D008970:Molecular Weight; D011467:Prostate / Q000032:analysis* / Q000166:cytology; D011470:Prostatic Hyperplasia / Q000378:metabolism; D029584:Prostatic Secretory Proteins; D011485:Protein Binding
D002352:Carrier Proteins; D003911:Dextrans; D029584:Prostatic Secretory Proteins; C028321:estramustine-binding protein; D002606:Charcoal